Daiichi Sankyo to close Japanese RnD subsidiary Daiichi Sankyo RD Novare

Tokyo: Daiichi Sankyo has announced that it has decided to close its Japanese research and development (R&D) subsidiary, Daiichi Sankyo RD Novare Co., Ltd. (headquartered in Edogawa-ku, Tokyo; hereinafter called “RD Novare”).

Daiichi Sankyo will absorb RD Novare's functions into its own organization further to strengthen its R&D capabilities. RD Novare (approx. 400 employees) was founded as Daiichi Sankyo RD Associe Co., Ltd. in 2006 to support Daiichi Sankyo’s drug discovery and clinical development.

In 2011, the company name was changed to the current one. 

RD Novare will conclude its business as a corporate entity on March 31, 2024. With this reorganization to further enhance the productivity of its R&D, Daiichi Sankyo will merge R&D strengths within the Daiichi Sankyo group of companies, leading to the construction and implementation of a consistent research strategy for drug discovery, rapid decision-making, and the strengthening of global clinical development for the 5DXd-ADCs, including ENHERTU.

Read also: Daiichi Sankyo Daichirona for Intramuscular Injection approved for manufacturing, marketing as booster vaccination in Japan

Daiichi Sankyo is an innovative global healthcare company with more than 120 years of experience.